Checked, not settled
Checks out so far.
“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55% objective response rate.”
1 of 4 review checks done · 1 counted
Supported · 0.9938 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited. The number is model-conditional, not a share of truth.
Share:
Checked in Galedra: score 0.99, strongly supported · not yet reviewed by anyone else
“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55%…”
https://galedra.org/claims/4ed04b41-aa3e-8b90-90df-f9f63f618936/card
Or just the link: https://galedra.org/claims/4ed04b41-aa3e-8b90-90df-f9f63f618936/card
See the evidence · 
Galedra